Clinical Trials Logo

Influenza, Human clinical trials

View clinical trials related to Influenza, Human.

Filter by:

NCT ID: NCT04315194 Completed - Clinical trials for Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination Therapy vs. Oseltamivir Alone for Hospitalised Paediatric Influenza Patients

Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination Therapy vs. Oseltamivir Alone for Hospitalised Paediatric Influenza Patients

Start date: December 18, 2017
Phase:
Study type: Observational [Patient Registry]

Efficacy of clarithromycin-naproxen-oseltamivir combination therapy vs. oseltamivir alone for hospitalised paediatric influenza patients

NCT ID: NCT04313946 Recruiting - COVID-19 Clinical Trials

Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays

AI-COVID-Xr
Start date: March 18, 2020
Phase:
Study type: Observational

This project aims to use artificial intelligence (image discrimination) algorithms, specifically convolutional neural networks (CNNs) for scanning chest radiographs in the emergency department (triage) in patients with suspected respiratory symptoms (fever, cough, myalgia) of coronavirus infection COVID 19. The objective is to create and validate a software solution that discriminates on the basis of the chest x-ray between Covid-19 pneumonitis and influenza

NCT ID: NCT04298060 Not yet recruiting - Influenza Infection Clinical Trials

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)

STOP-Flu
Start date: July 2020
Phase: Phase 2
Study type: Interventional

This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.

NCT ID: NCT04297462 Recruiting - Influenza Clinical Trials

Different Regimens in Influenza Postexposure Chemoprophylaxis in Children

Start date: November 17, 2016
Phase: N/A
Study type: Interventional

Although the vaccination is the preferred method of influenza prevention, there are some occasions on which a postexposure prophylaxis (PEP) is required. Two neuraminidase inhibitors (NAIs) may be used in chemoprophylaxis in children: oral oseltamivir, and inhaled zanamivir. Both, oseltamivir and zanamivir, are effective in treatment and in prophylaxis of influenza, and the efficacy is calculated to reach 70-90%. Oseltamivir is used more frequently, since zanamivir is licensed in older children (5 years of age and above), and children under the age of 5 years are at higher risk of influenza complications. Oseltamivir use correlated in children with higher risk of vomiting, with no increased risk of other adverse events, including those observed in adult patients (nausea, renal events, and psychiatric effects). The PEP may be indicated by individual patient's characteristics (e.g. patients in high-risk group) or epidemiological reasons, i.e. prevention of institutional outbreaks.The one research that analyzed efficacy of 3-days PEP versus 7 or 10-days and showed overall efficacy of shorter oseltamivir prophylaxis to be high and comparable to that of longer regimens. The study included several pediatric patients and made the investigators perform such an analysis in pediatric population. In this randomized controlled trial, the investigators aimed to compare efficacy, safety, and costs of 3 versus 7-days prophylaxis with oral oseltamivir in children hospitalized. The hypothesis is that 3-days duration of PEP is not less effective than 7-days PEP, and patients might gain from lower number of adverse reactions related to drug administration.

NCT ID: NCT04288921 Recruiting - Influenza, Human Clinical Trials

Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites

INSPIRE
Start date: February 6, 2020
Phase: N/A
Study type: Interventional

A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx Influenza A/B + RSV Test at Point of Care Testing Sites

NCT ID: NCT04282135 Completed - Influenza Clinical Trials

Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling

Start date: February 15, 2020
Phase:
Study type: Observational

Multicapillary Ion mobility spectrometry of nasal air aspirates shall be investigated as screening tool for the detection of Influenza and SARS-CoV-2- infection.

NCT ID: NCT04250311 Suspended - Influenza Clinical Trials

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

Start date: December 12, 2019
Phase: Phase 3
Study type: Interventional

The main purpose of this study is: • to evaluate the efficacy and safety of MMH-407 in the treatment of influenza in outpatient adults.

NCT ID: NCT04245800 Completed - Clinical trials for Respiratory Tract Infections

Home Testing of Respiratory Illness

Start date: December 13, 2019
Phase:
Study type: Observational

The main goal of this research study is to use data from activity trackers (such as Fitbits), lab tests, and surveys to see if activity, sleep, and heart rate data can tell the difference between when someone has a respiratory illness (e.g., flu) and when they are feeling healthy. The research will also study an investigational flu@home test and app. If successful, results from the study could be used in the future to better identify people with respiratory illness. In addition, this study will test the accuracy of an at-home flu test kit compared to laboratory test results.

NCT ID: NCT04244500 Recruiting - Influenza, Human Clinical Trials

Burden of Influenza at Emergency Department (ED) Level in European Countries

Start date: January 27, 2020
Phase:
Study type: Observational

This study plans to conduct enhanced influenza surveillance at a hospital emergency department level independent of underlying influenza-like symptoms.

NCT ID: NCT04232956 Completed - Influenza Clinical Trials

Invasive Pulmonary Aspergillosis and Severe Influenza

ASPERGIGRIPP
Start date: July 27, 2018
Phase:
Study type: Observational

Invasive pulmonary aspergillosis (IPA) has been reported in critically ill patients with influenza infection with a highly variable incidence between 1 to 21%. Studies investigating IPA in critically ill patients with influenza infection suffer limitations in their methods. It remains unknown whether patients with influenza are more at risk of IPA than other patients hospitalized in intensive care unit and whether patients with influenza who develop IPA have specific risk factors for this infection. Our study aims to determine the incidence of IPA in a large multicenter cohort and to identify risk factors for IPA in these patients.